The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

A woman in her late 30s presented with a complaint of not being able to palpate the subdermal contraceptive implant in her left arm, which was inserted 6 years earlier. An x-ray revealed a ...